Researchers at the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), have identified an experimental medication that achieves strong pain relief without the risks typically associated with opioids. The research team studied a compound called DFNZ, a metabolite derived from nitazene, and published their findings in the journal Nature.
Novel Pharmacology and Benefits
In preclinical studies using animal models, DFNZ provided at least two hours of pain relief in mice after just five or 10 minutes in the brain. Unlike standard opioids, the drug did not produce respiratory depression—a dangerous side effect where breathing becomes too slow, shallow, or ineffective, causing carbon dioxide to build up in the body. At therapeutic doses, DFNZ produced a moderate and sustained increase in brain oxygen rather than depressing respiration.
Safety Profile
Repeated doses of DFNZ did not result in tolerance, drug dependency, or meaningful withdrawal effects. The only classic opioid withdrawal symptom observed was irritability. According to the research, DFNZ binds tightly to the opioid receptor but does not cause breathing suppression or addiction, and releases dopamine more gradually than standard opioids. Michael Michaelides, Ph.D., senior author and NIDA investigator, stated that “DFNZ has an unprecedented pharmacology for an opioid. It is a potent and high-efficacy analgesic, but in certain contexts it resembles partial agonists, drugs that activate the receptor with low efficacy, which is what scientists think is needed for safety.”
Potential Applications and Next Steps
Researchers suggest DFNZ could potentially be used as a safer treatment for opioid use disorder as well as for patients undergoing surgery and experiencing cancer-related or chronic pain. However, the study had significant limitations, including being conducted solely with animal models. The effectiveness and safety of human use remains unknown, and the study did not explore long-term impacts or rare adverse effects. The research team plans to conduct additional preclinical studies before seeking regulatory approval for human clinical trials.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.foxnews.com/health/new-safer-opioid-delivers-pain-relief-without-addiction-risk-early-tests